Quick Answer
Humacyte, Inc. reported R&D Expense of $69.30 million for fiscal year 2025.
Humacyte, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $69.30M | -21.8% |
| 2024 | $88.60M | +15.7% |
| 2023 | $76.55M | +21.0% |
| 2022 | $63.26M | +3.1% |
| 2021 | $61.34M | +13.4% |
| 2020 | $54.08M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $17.27M | -24.7% | -21.5% |
| June 30, 2025 | $22.01M | -7.4% | +42.7% |
| March 31, 2025 | $15.42M | -27.5% | -32.7% |
| September 30, 2024 | $22.93M | +23.6% | -3.5% |
| June 30, 2024 | $23.75M | +15.6% | +11.7% |
| March 31, 2024 | $21.26M | +23.1% | +14.6% |
| September 30, 2023 | $18.55M | +7.0% | -9.7% |
| June 30, 2023 | $20.54M | +40.2% | +18.9% |
- Humacyte, Inc. showed a decrease of -21.8% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Humacyte, Inc.’s r&d expense has grown by 28.2% (from $54.08 million to $69.30 million).
- The most recent figure is from Humacyte, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: